Skip to main content

Talk Bio

Search This Blog

Pfizer signs up to $10.5B deal with Innovent for 12 early‑stage cancer drugs from China's biotech hub

on May 29, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

Pfizer has signed a strategic global licensing and collaboration agreement with China's Innovent Biologics on 12 early-stage cancer medicines, in a deal valued at up to $10.5 billion.

The portfolio includes eight Innovent-originated assets and four Pfizer-proposed discovery programs, all centered on antibody–drug conjugates (ADCs) and multi-specific antibodies.

Innovent will lead development through Phase 1 trials; Pfizer will then take over global development and commercialization, with various rights and cost‑sharing structures across the 12 programs.

Innovent receives $650 million upfront and is eligible for up to $9.85 billion in milestone payments, plus double‑digit royalties on any future sales.

Sources:

Innovent and Pfizer partner to co-develop 12 ne... - Pluang

Pfizer, Innovent strike $10B cancer drug deal | BioPharma Dive

Pfizer Strikes Up To $10.5 Billion Deal With Innovent Biologics

Pfizer and Innovent Biologics Enter Global Strategic Collaboration to ...

Pfizer and Innovent Biologics Enter Global Strategic Collaboration to ...

Innovent Biologics, Pfizer strike $10.5 billion cancer drug deal amid China biotech boom

China’s Innovent Biologics signs US$10.5b Pfizer deal for 12 cancer drug trials

Pfizer, Innovent Sign Licensing Deal to Develop 12 Cancer Drugs

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to ...

China’s Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal

Pfizer and Innovent Biologics strike $10.5bn oncology deal spanning 12 cancer programmes

Pfizer and Chinese Innovent Biologics sign cancer deal worth up to ...

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

cancer medicines Innovent Biologics milestone payments Pfizer royalties upfront payment

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

Xaira Therapeutics Launches X-Cell: First AI Virtual Cell Model Testing Scaling Laws on Massive Perturbation Data

Xaira Therapeutics announced X-Cell on March 17, 2026, a 4.9-billion-parameter diffusion language model, the largest virtual cell model to date, trained on X-Atlas/Pisces, the largest genome-wide CRISPRi Perturb-seq dataset with 25.6 million perturbed single-cell transcriptomes across seven diverse contexts. 1 2 X-Cell predicts cell responses to genetic perturbations, outperforming existing models by up to five-fold on metrics like Pearson delta, and generalizes zero-shot to unseen biological contexts such as iPSC-derived melanocyte progenitors and primary human CD4+ T cells. 1 2 The model follows power-law scaling dynamics similar to large language models, using a novel diffusion architecture that iteratively refines predictions. 2 Xaira, founded in 2024 with over $1 billion funding, plans to expand X-Atlas to primary cells, organoids, and in vivo perturbations, focusing on inflammatory/immunological diseases and antibody therapeutics. 1 3 A subset of the Pisces dataset and X-...

Ultragenyx Resubmits BLA for UX111 Gene Therapy with New Long-Term Data for Sanfilippo Syndrome Type A

Ultragenyx resubmitted its Biologics License Application (BLA) to the FDA for UX111, an AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA), including long-term clinical data on neurologic, biomarker, and safety improvements. 1 2 3 4 5 The resubmission addresses a Complete Response Letter from July 2025 related to manufacturing (CMC) observations and adds durable biomarker reductions, such as CSF heparan sulfate, with favorable safety profile. 2 4 5 FDA's six-month priority review has begun; PDUFA action date expected in Q3 2026. 2 4 5 If approved, UX111 would be the first therapy for this fatal pediatric neurodegenerative disorder. 1 3 4 5 New long-term data announced February 3, 2026, shows substantial biomarker improvements and functional benefits vs. natural history, consistent across age and severity. 2 Sources: 1. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-bla-resubmission-puts-ux111-and-ra...

Powered by Blogger

X-Data LLC